Maynard Um
-
-
-
-
-
-
-
Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold
-
-
-
-
-
-
-
Goldman Sachs Reiterates Early-Stage Biotech Rating on Fulcrum Therapeutics (FULC)
-
-
-
-
-
-
-
After-hours movers: NVIDIA, Toll Brothers, and more
-
-
-
-
-
-
-
Fulcrum Therapeutics (FULC) PT Raised to $10 at RBC Capital
-
-
-
-
-
-
-
Fulcrum Therapeutics (FULC) PT Raised to $16 at Leerink Partners
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Fulcrum Therapeutics (FULC)
-
-
-
-
-
-
-
Fulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod
-
404,858 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

